Shantel
Key Takeaways
- Persist AI closes a $4M oversubscribed financing round following their YCombinator completion, with significant backing from key investors.
- Leveraging AI-driven automation, Persist AI has managed to cut traditional drug formulation timelines in half.
- Persist AI’s automated development of long-acting injectable formulations signals a transformative leap for the future of drug development.
About Persist AI
Persist AI is an AI-driven pioneer in the realm of drug formulation, specializing in building and optimizing long-acting injectable formulations. They provide high-throughput formulation screening, automated drug release testing, method transfer, and manufacturing scale-up solutions, effectively addressing drug clearance, formulation instability, acute toxicity, shelf life, and a myriad of drug formulation-related problems.
Accelerating the Pace of Drug Formulation
Conventional pharmaceutical companies may take up to five years to formulate long-lasting drug injections for chronic conditions like cancer and diabetes. However, Persist AI is dramatically changing this paradigm. Using advanced AI-driven automation, Persist AI is halving the formulation development timeline, reducing it to just two years. “We complete microsphere pre-formulation for clients in weeks, not years,” stated CEO Karthik Raman, hinting at the disruptive power of their technology.
Over the past six months, Persist AI has developed cutting-edge robotics that streamline the development of long-acting injectable formulations. When merged with AI models, these robots can swiftly predict which formulations will allow drugs to be released in the body over an extended period, thereby reducing the number of injections patients need.
Investing in a Healthier Future
The innovative approach of Persist AI has not gone unnoticed by venture capital firms. The recent oversubscribed $4M financing round was led by 2048 Ventures, with notable participation from Innospark Ventures, Fellows Fund, YCombinator, Pioneer Fund, among others.
Alex Iskold, Managing Partner of 2048 Ventures, expressed enthusiasm about their investment, saying, “Drug formulation has long been overlooked despite being a crucial part of drug development. Persist’s technology allows them to rapidly screen formulations, develop AI models that optimize the formulations, and then scale up formulations for human clinical use. We’re excited to invest in this groundbreaking technology.”
Innospark Ventures’ Partner, Matt Fates, echoes these sentiments, stating, “Persist AI’s disruptive approach to drug formulation holds immense promise for the future of drug development.” Their AI-driven technology is set to revolutionize how we develop and optimize formulations for therapeutics of all kinds. We are proud to support their vision and contribute to their success.”
Looking Ahead
Persist AI is more than a testament to the transformative power of AI; it represents a pivotal shift in drug formulation. Their technology not only speeds up the development of long-lasting injections but also enhances their efficacy, ensuring drugs are optimally released in the body. It’s a game-changing approach that could fundamentally transform how chronic conditions are managed.
As Persist AI continues to evolve and their cutting-edge AI technology is applied to the development and optimization of formulations for all types of therapeutics, the impact on drug formulation and patient care could be profound. As Matt Fates of Innospark Ventures puts it, the future of drug development holds “immense promise.”
For more information about Persist AI and their revolutionary approach to drug formulation, please visit their website or contact them directly.
